Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07161830 · ClinicalTrials.gov registry record · NA

Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

A NA study of Diabetic Foot Ulcer, sponsored by Omeza.

Recruiting
Registry status
NA
Development phase
130
Enrollment target
3
Study locations

NCT07161830 is a NA study of Diabetic Foot Ulcer that is actively recruiting participants, run by Omeza. The registered enrollment target is 130 participants, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (49% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07161830, a NA study of Diabetic Foot Ulcer, is actively recruiting participants, sponsored by Omeza.

RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
3
Study locations

Study Summary

This study aims to compare two treatment approaches for diabetic foot ulcers (DFUs): the standard of care (SOC) alone versus SOC combined with OCM. Researchers will evaluate whether adding OCM increases the likelihood of ulcers healing completely by the end of the trial period.

Conditions Studied

Interventions

  • OTHER Standard of Care
  • DEVICE Omeza® Complete Matrix

Study Locations (3)

Louisiana

  • MedCentris of Denham Springs - Denham Springs
  • MedCentris of Leesville - Leesville

Mississippi

  • MedCentris of Southaven - Southaven

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-12-04
Est. Completion 2027-03-30
Phase NA

Sponsor

Omeza

6 total trials

What the Registry Record Tells You About NCT07161830

The ClinicalTrials.gov registry entry for NCT07161830 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (49% lower). The listed sponsor is Omeza, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT07161830 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, Mississippi.

Frequently Asked Questions

What is clinical trial NCT07161830 about?

NCT07161830 is a clinical study titled "Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers". This study aims to compare two treatment approaches for diabetic foot ulcers (DFUs): the standard of care (SOC) alone versus SOC combined with OCM. Researchers will evaluate whether adding OCM increases the likelihood of ulcers healing completely by the end of the trial period.

What is the current status of trial NCT07161830?

This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-12-04. Estimated completion is 2027-03-30.

What conditions does trial NCT07161830 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer.

What interventions are being tested in trial NCT07161830?

The interventions under investigation include: Standard of Care (OTHER), Omeza® Complete Matrix (DEVICE).

Who is sponsoring clinical trial NCT07161830?

This trial is sponsored by Omeza, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07161830 being conducted?

This trial has 3 study locations across Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.